SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects

Efficacy and side effects of hydroxyurea in patients with thalasemia

Introduction: The β-thalassaemias represent a heterogenous group of diseases resulting from decreased β-globin mRNA expression and imbalanced alpha/betaglobin chain synthesis which are clinically manifested by ineffective erythropoiesis and excessive hemolysis. Increasing levels of hemoglobin F (HbF) by improving the balance in globin chain synthesis. Hydroxyurea (HU), as an effective with lo...

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

Diabetic nephropathy (DN) affects an estimated 20%-40% of patients with type 2 diabetes mellitus (T2DM). Key modifiable risk factors for DN are albuminuria, anaemia, dyslipidaemia, hyperglycaemia and hypertension, together with lifestyle factors, such as smoking and obesity. Early detection and treatment of these risk factors can prevent DN or slow its progression, and may even induce remission...

SGLT2 Inhibitors and the Diabetic Kidney.

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...

Phosphodiesterase-5 Inhibitors: Potential Nephroprotective Agents

Zaher Armaly1 and Zaid Abassi2,3* 1Departmentof Nephrology, EMMS Nazareth–The Nazareth Hospital, Nazareth and Galilee Medical School-Bar Ilan University, Safed, Israel 2Research Unit, Rambam Health Care Campus Haifa, Israel 3Department of Physiology, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel *Corresponding author: Zaid Abassi, Department of Physiology...

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs